Immunity against SARS-CoV-2 in immune-suppressed patients: increased risk of insufficient immunological memory or sufficient protection against re-infection?

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $320,331.76
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Amsterdam University Medical Center - location AMC
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Patients with autoimmune diseases often use immunosuppressive medication. The effect of these treatments on the development and maintenance of adequate immunity after a previous COVID-19 infection and on the upcoming vaccines against Covid-19 is unknown. Research and expected outcomes First of all, COVID-19 specific immunity is investigated in patients and healthy people after a previous COVID-19 infection. In the second phase, the response to a COVID-19 vaccination is compared between infected patients and healthy people. In addition, this response is compared to patients and healthy people without prior COVID-19 infection. With these results, the hope is to determine the effect of different types of immunosuppressant medications on immunity to COVID-19, so that advice can be provided on the optimal vaccination strategy in the many immunosuppressed patients. This study is a collaboration between several university centers, Sanquin Blood Supply and the RIVM (Target to B consortium, T2B).